Rx News

FDA Approves Generic Version of Sanctura XR

June 5, 2013

Sanctura XR is a medication that may be prescribed to treat symptoms of an overactive bladder. By blocking certain receptors in the bladder and relaxing the muscles of the bladder, the drug can help treat frequent urination, frequent urges to urinate, and leaking accidents. The medication comes in the form of a capsule that is taken once a day. Possible side effects include dry mouth, constipation, and dry eyes.

As of May 29, 2013, Perrigo Company announced that it has received final approval for the generic version of Sanctura XR. Perrigo had previously prevailed in litigation at both the district and appellate levels. The product has begun shipping immediately.

Sanctura XR is a once-daily medication for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency and has annual sales of approximately $54 million, as measured by Symphony Health Solutions.

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This is another example of Perrigo's commitment to bring new products to market. Perrigo continues to deliver on its mission to provide quality, affordable healthcare to consumers."

From its beginnings as a packager of generic home remedies in 1887, Allegan, Michigan-based Perrigo Company has grown to become a leading global provider of quality, affordable healthcare products. Perrigo develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements and active pharmaceutical ingredients (API) .